Skip to content
ARCT·Nasdaq·US

Arcturus Therapeutics

Arcturus Therapeutics is a messenger RNA medicines company focused on developing liver and respiratory rare disease therapeutics, with ongoing Phase 2 clinical studies for RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis. The company also developed the world's first approved self-amplifying messenger RNA vaccine, KOSTAIVE, which it has partnered with Seqirus, Inc., part of CSL Limited.

Source: SEC 10-K Mar 3, 2026

Thematic Position

ARCT

Relationship Groups

Suppliers1
Partners2
Licensing1
Competitors9

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

5 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

government rightsmarch-in rightsIP constraint
U.S. government Bayh-Dole march-in rights over government-funded inventions
SEC 10-KMar 3, 2026

The full regulatory passage is part of the Pro plan.

4 more · Regulatory and geopolitical insights are part of the Pro plan.

Disclosed customers above 10% of revenue

1 customer · Named major customers are part of the Pro plan.